{
    "ticker": "FXR",
    "name": "Flexion Therapeutics, Inc.",
    "description": "Flexion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for patients with musculoskeletal conditions. Founded in 2010 and headquartered in Burlington, Massachusetts, Flexion is dedicated to improving the quality of life for patients suffering from pain related to osteoarthritis and other joint-related issues. The company\u2019s lead product, Zilretta, is a unique, extended-release formulation of triamcinolone acetonide designed to provide long-lasting pain relief for patients with knee osteoarthritis. Zilretta has received FDA approval and is marketed to healthcare providers and patients across the United States. Flexion is committed to advancing its pipeline of therapies, which includes both injectable and oral formulations aimed at addressing unmet needs in pain management. The company emphasizes a patient-centric approach, working closely with healthcare professionals to ensure that their products meet the specific needs of patients. With a strong focus on innovation and clinical excellence, Flexion aims to be a leader in the field of pain management, striving to enhance the treatment landscape for musculoskeletal disorders and improve patient outcomes.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Burlington, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.flexiontherapeutics.com",
    "ceo": "Michael Clayman",
    "social_media": {
        "twitter": "https://twitter.com/FlexionThera",
        "linkedin": "https://www.linkedin.com/company/flexion-therapeutics/"
    },
    "investor_relations": "https://investors.flexiontherapeutics.com",
    "key_executives": [
        {
            "name": "Michael Clayman",
            "position": "CEO"
        },
        {
            "name": "Lynn K. M. S. Heslop",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Zilretta"
            ]
        }
    ],
    "seo": {
        "meta_title": "Flexion Therapeutics, Inc. | Innovative Pain Management Solutions",
        "meta_description": "Explore Flexion Therapeutics, Inc., a leader in biopharmaceuticals focused on innovative treatments for musculoskeletal pain. Learn about Zilretta and our commitment to patient care.",
        "keywords": [
            "Flexion Therapeutics",
            "Zilretta",
            "Pain Management",
            "Osteoarthritis",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Flexion Therapeutics known for?",
            "answer": "Flexion Therapeutics is known for developing Zilretta, an extended-release formulation for managing knee osteoarthritis pain."
        },
        {
            "question": "Who is the CEO of Flexion Therapeutics?",
            "answer": "Michael Clayman is the CEO of Flexion Therapeutics, Inc."
        },
        {
            "question": "Where is Flexion Therapeutics headquartered?",
            "answer": "Flexion Therapeutics is headquartered in Burlington, Massachusetts, USA."
        },
        {
            "question": "What are Flexion's main products?",
            "answer": "Flexion's main product is Zilretta, which is used for pain management in patients with knee osteoarthritis."
        },
        {
            "question": "When was Flexion Therapeutics founded?",
            "answer": "Flexion Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "AMGN",
        "ABT",
        "PFE",
        "JNJ"
    ],
    "related_stocks": [
        "GILD",
        "MRNA",
        "VRTX",
        "BIIB"
    ]
}